Table 1

Blood:plasma concentration ratio of paclitaxel in the absence and presence of various concentrations of CrEL, castor oil, and HPLC fractions of CrELa

Compound added (%)Blood:plasma ratioPercentage change vs. control (%)Pb
None1.07 ± 0.004
CrEL (0.01)1.09 ± 0.009+1.830.387
CrEL (0.05)0.990 ± 0.015−9.350.012
CrEL (0.10)0.901 ± 0.017−15.80.003
CrEL (0.50)0.690 ± 0.005−35.5<0.0001
CrEL (1.0)0.625 ± 0.008−41.6<0.0001
Castor oil (0.50)1.23 ± 0.171+13.00.061
CrEL fraction 1 (0.50)1.06 ± 0.008−0.940.520
CrEL fraction 2 (0.50)0.926 ± 0.018−13.50.043
CrEL fraction 3 (0.50)0.763 ± 0.055−28.70.010
CrEL fraction 4 (0.50)0.645 ± 0.051−39.70.003
CrEL fraction 5 (0.50)0.943 ± 0.039−11.90.103
  • a Paclitaxel was used at an initial concentration of 1 μg/ml and incubated in whole blood for 15 min at 37°C before fractionation and HPLC analysis. Ratio data are presented as mean values ± SD of (at least) triplicate measurements.

  • b Probability value versus control (unpaired two-sided Student’s t test).